An update and baseline data from the phase 2/3 GAIN trial of COR388 (atuzaginstat), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease

Alzheimer s & Dementia ◽

10.1002/alz.050624 ◽

2021 ◽

Vol 17 (S9) ◽

Author(s):

Mike Detke

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Virulence Factor ◽

Bacterial Virulence ◽

Baseline Data ◽

Phase 2 ◽

Factor Inhibitor ◽

Bacterial Virulence Factor

Download Full-text

P4-663: INITIATION OF THE PHASE 2/3 GAIN TRIAL OF COR388, A NOVEL BACTERIAL VIRULENCE FACTOR INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD) BASED ON PHASE I A/B SAFETY, PK, BIOMARKER AND EFFICACY DATA

Alzheimer s & Dementia ◽

10.1016/j.jalz.2019.09.029 ◽

2019 ◽

Vol 15 ◽

pp. P1585-P1585

Author(s):

Mike Detke ◽

Casey Lynch ◽

Leslie Holsinger ◽

Shirin Kapur ◽

Dave Hennings ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase I ◽

Virulence Factor ◽

Bacterial Virulence ◽

Phase 2 ◽

Efficacy Data ◽

Factor Inhibitor ◽

Bacterial Virulence Factor

Download Full-text

Faculty Opinions recommendation of Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732699317.793576065 ◽

2020 ◽

Author(s):

Filippo Drago ◽

Filippo Caraci

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Blind Study ◽

Double Blind Study ◽

Phase 2 ◽

Download Full-text

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Nature Aging ◽

10.1038/s43587-021-00070-2 ◽

2021 ◽

Vol 1 (6) ◽

pp. 521-534

Author(s):

Petr Novak ◽

Branislav Kovacech ◽

Stanislav Katina ◽

Reinhold Schmidt ◽

Philip Scheltens ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Active Immunotherapy ◽

Phase 2 ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Purification of bacterial virulence factor pertactin using high affinity ligands

Biochemical Engineering Journal ◽

10.1016/j.bej.2020.107760 ◽

2020 ◽

Vol 164 ◽

pp. 107760

Author(s):

Umatheny Umatheva ◽

Braden Sweeting ◽

Léo Sauvaget ◽

Nerissa Dela Rosa ◽

John Riley ◽

...

Keyword(s):

Virulence Factor ◽

Bacterial Virulence ◽

Affinity Ligands ◽

High Affinity ◽

Bacterial Virulence Factor

Download Full-text

Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer’s disease: rationale, design, methods, and first baseline data of the Vogel study

Journal of Neural Transmission ◽

10.1007/s00702-017-1781-0 ◽

2017 ◽

Vol 124 (11) ◽

pp. 1473-1488 ◽

Author(s):

Thomas Polak ◽

Martin J. Herrmann ◽

Laura D. Müller ◽

Julia B. M. Zeller ◽

Andrea Katzorke ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Infrared Spectroscopy ◽

Early Diagnosis ◽

Evoked Potentials ◽

Near Infrared Spectroscopy ◽

Somatosensory Evoked Potentials ◽

Near Infrared ◽

Design Methods ◽

Download Full-text

Secretion of a bacterial virulence factor is driven by the folding of a C-terminal segment

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.1009491107 ◽

2010 ◽

Vol 107 (41) ◽

pp. 17739-17744 ◽

Author(s):

Janine H. Peterson ◽

Pu Tian ◽

Raffaele Ieva ◽

Nathalie Dautin ◽

Harris D. Bernstein

Keyword(s):

Virulence Factor ◽

Terminal Segment ◽

Bacterial Virulence ◽

Bacterial Virulence Factor

Download Full-text

O4-11-04: LINKING DIABETES AND ALZHEIMER'S DISEASE THROUGH RAGE: A RETROSPECTIVE ANALYSIS OF AZELIRAGON PHASE 2 AND PHASE 3 STUDIES

Alzheimer s & Dementia ◽

10.1016/j.jalz.2019.06.4803 ◽

2019 ◽

Vol 15 ◽

pp. P1263-P1263 ◽

Author(s):

Carmen Valcarce ◽

Imogene Dunn ◽

Aaron H. Burstein

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Retrospective Analysis ◽

Phase 2 ◽

Download Full-text

Longitudinal flortaucipir accumulation is spatially distinct across baseline tau burden stages: Summary from three phase 2/3 interventional trials in Alzheimer’s disease

Alzheimer s & Dementia ◽

10.1002/alz.041815 ◽

2020 ◽

Vol 16 (S4) ◽

Author(s):

Sergey Shcherbinin ◽

Ixavier A. Higgins ◽

Ming Lu ◽

Michael J. Pontecorvo ◽

Albert C. Lo ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Phase 2 ◽

Download Full-text

P1-392: DRUG DEVELOPMENT FOR AGITATION AND AGGRESSION IN ALZHEIMER'S DISEASE (AD): STUDY DESIGN AND OUTCOME MEASURES IN PHASE 2 STUDY OF SCYLLO-INOSITOL (ELND005 STUDY AG201)

Alzheimer s & Dementia ◽

10.1016/j.jalz.2014.05.634 ◽

2014 ◽

Vol 10 ◽

pp. P458-P458 ◽

Author(s):

Susan R. Abushakra ◽

Patrick Kesslak ◽

Matthias Kurth ◽

Frank Fan ◽

Menghis Bairu ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Drug Development ◽

Outcome Measures ◽

Study Design ◽

Phase 2 ◽

Download Full-text

P2-067: Modifications in Albumin Molecular Profile in a Phase 2 Study Based on Therapeutic Plasma Exchange and 5% Albumin Replacement in Alzheimer's Disease

Alzheimer s & Dementia ◽

10.1016/j.jalz.2016.06.1272 ◽

2016 ◽

Vol 12 ◽

pp. P633-P634

Author(s):

Montserrat Costa ◽

Ana María Ortiz ◽

Raquel Horrillo ◽

Alba Pérez ◽

Mercè Boada ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Plasma Exchange ◽

Therapeutic Plasma Exchange ◽

Molecular Profile ◽

Phase 2 ◽

Download Full-text